Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Dr. Stefan Scherer, M.D., Ph.D., to the role of Senior Vice President Clinical Development and Deputy Chief Medical Officer. Dr. Scherer joins Cellectis from Novartis Pharmaceuticals Corporation, where he was the Head of Early Development, Strategy and Innovation for U.S. Oncology.
Cellectis Appoints Stefan Scherer
AppointmentsCellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Dr. Stefan Scherer, M.D., Ph.D., to the role of Senior Vice President Clinical Development and Deputy Chief Medical Officer. Dr. Scherer joins Cellectis from Novartis Pharmaceuticals Corporation, where he was the Head of Early Development, Strategy and Innovation for U.S. Oncology.
Arix Bioscience acquires 11% stake in Phamaxis Ltd.
Latest NewsAn investor consortium led by British Arix Bioscience plc has put £13.4m into the Australian Pharmaxis Ltd, which develops fibrosis inhibitors based on its amine oxidase discovery platform.
Getting ready for Brexit
Latest NewsAs UK’s departure from the EU is fast approaching, stakeholders are preparing for the disruption a hard Brexit might cause. While EMA is scaling back activities, pharma companies are stockpiling meds.
Nanobots: Fiction becoming reality
BackgroundOnce confined to speculative and science fiction, miniature micro- or nanobots targeting pathogens or conditions directly have now become reality in research labs worldwide. But to enter clinical trials, scientists still have to overcome two major hurdles – visualising the tiny machines inside the body, and preventing a potential immune response.
Cell Medica Appoints New CEO
AppointmentsCell Medica, a company active in the development, manufacture and marketing of personalised cellular immunotherapeutics for the treatment of cancer, has appointed Chris Nowers as Chief Executive Officer and Executive Director.
ReViral raises US$55m
Latest NewsAntiviral drug discovery company ReViral announced the successful completion of a of a US$55m Series B financing. The funding will go toward clinical studies for its respiratory tract infection treatment.
EU’s single-use plastic rules boost bioplastics
Latest NewsThe global market value of biodegradable plastics has passed the US$1.1bn mark in 2018, a report by IHS Markit says. More than half of the demand comes from Western Europe, driven by increasing regulation.
Marinomed Biotech Appoints New CFO
AppointmentsPascal Schmidt appointed CFO as Vienna based biotech firm Marinomedas of August 1 2018.
Kick Off Vetter’s New Innovation Challenge
Sponsored PublicationsVetter strikes out on new pathways to further develop the injection process.
CDMO launches the Vetter Open Innovation Challenge under the slogan Injection 2.0′
First migraine prevention drug hits EU market
Latest NewsSwiss pharma giant Novartis announced that its monoclonal antibody for migraine prevention Aimovig (erenumab) has received market approval in the EU. It is the first treatment of its kind to be available here.